A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
-
Wainberg, Zev A. (David Geffen School of Medicina, UCLA (USA))
;
Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ;
Soares, Heloisa P. (Moffitt Cancer Center (USA)) ;
Braña, Irene (Princess Margaret Cancer Centre (Canada)) ;
Britten, Carolyn D. (Medical University of South Carolina (USA)) ;
Del Conte, Gianluca (IRCCS Ospedale San Raffaele(Italy)) ;
Ezeh, Patrick (Pfizer Oncology (USA)) ;
Houk, Brett (Pfizer Oncology (USA)) ;
Kern, Kenneth A. (Pfizer Oncology (USA)) ;
Leong, Stephen (University of Colorado (USA)) ;
Pathan, Nuzhat (Pfizer Oncology, 10646 Science Center Drive, San Diego, CA 92121 USA) ;
Pierce, Kristen J. (Pfizer Oncology (USA)) ;
Siu, Lillian L. (Princess Margaret Cancer Centre (Canada)) ;
Vermette, Jennifer (Pfizer Oncology (USA)) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
visitant ::
identificació
Subscriure's to this discussion. You will then receive all new comments by email.
